To explore the prognostic and/or predictive value of human epidermal growth factor receptor @ ( HER@ ) pathway-related biomarkers in the phase III CLEOPATRA study of pertuzumab plus trastuzumab plus docetaxel versus placebo plus trastuzumab plus docetaxel as first-line treatment for patients with HER@-positive metastatic breast cancer .